Select Language
CD79B
CD79B Overview
| English Name | B-cell antigen receptor complex-associated protein beta chain | Approved Drugs | 1 |
| Drugs in Clinical Trials | 9 | Target Synonym | B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6 |
| Highest Development Stage | Approved | ||
| English Name | B-cell antigen receptor complex-associated protein beta chain |
| Target Synonym | B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 9 |
| Highest Development Stage | Approved |
CD79B Product List
- Product Category
Protein (9)Cell (1)
- Product Status
Launched (10)
- Species
Human (5)Mouse (3)Cynomolgus (2)
- Tag
Fc Tag (2)His Tag (4)His Tag & Avi Tag (3)- (1)
- Conjugate
Unconjugated (5)Biotin-labeled (3)PE Labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CDB-H5259 |  Human | HEK293 | Human CD79B Protein, Fc Tag |  |  |  |  Add to Cart |
HOT CDB-H52H3 | Human | HEK293 | Human CD79B Protein, His Tag, low endotoxin (MALS verified) |  | | | Add to Cart |
HOT CDB-H82E3 | Human | HEK293 | Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified) |  | | | Add to Cart |
HOT CDB-HP2H6 | Human | HEK293 | PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation) |  | Add to Cart | ||
SCCHO-ATP171 | Human | CHO | CHO/Human CD79B Stable Cell Line |  | Add to Cart | ||
CDB-M5253 |  Mouse | HEK293 | Mouse CD79B Protein, Fc Tag (MALS verified) |  | | Add to Cart | |
CDB-M52H4 | Mouse | HEK293 | Mouse CD79B Protein, His Tag, low endotoxin (MALS verified) |  | | Add to Cart | |
CDB-M82E3 | Mouse | HEK293 | Biotinylated Mouse CD79B Protein, His,Avitag™ (MALS verified) |  | | Add to Cart | |
CDB-C52H3 |  Cynomolgus | HEK293 | Cynomolgus CD79B Protein, His Tag (MALS verified) |  | | | Add to Cart |
CDB-C82E5 | Cynomolgus | HEK293 | Biotinylated Cynomolgus CD79B Protein, His,Avitag™ |  | | Add to Cart |
Total: 10
- 1
CD79B Background
B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
CD79B Synonyms
CD79b,B29,IGB,Ig-beta
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PRV-3279 | HDM-3002; MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Lupus Erythematosus, Systemic | Details |
| CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| TolDCB29 | Phase 2 Clinical | Umc Utrecht | Arthritis, Rheumatoid | Details | |
| SHR-A1912 | SHR-A1912 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma | Details |
| LTZ-301 | LTZ-301 | Phase 1 Clinical | Autoimmune Diseases; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
| Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy（MD Anderson Cancer Center） | JV-213 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma | Details |
| NBT-508 | Phase 1 Clinical | Newbio Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| CD79b CAR-T cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Polatuzumab vedotin | RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 | Approved | Seagen Inc, Genentech Inc | Polivy | United States | Lymphoma, Large B-Cell, Diffuse | Genentech Inc | 2019-06-10 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland